stella
beta
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy — Stella
Recruiting
Back to Nasopharyngeal Cancinoma (NPC) trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Fudan Universtiy Shanghai Cancer Centre, Shanghai, China
View full record on ClinicalTrials.gov